

Early death and intracranial hemorrhage prediction in acute promyelocytic leukemia: validation of a risk score in a cohort from an international consortium treated with chemotherapy plus all-*trans* retinoic acid

Authors

Wellington F. Silva,¹ Haesook T. Kim,² Maria S. Undurraga,³ Juan R. Navarro-Cabrera,⁴ Victor Salinas,⁵ Pablo Muxi,⁶ Raul A.M. Melo,⁷ Ana Beatriz F. Gloria,⁸ Katia B.B. Pagnano,⁹ Elenaide C. Nunes,¹⁰ Rosane Isabel Bittencourt,¹¹ Ninoska Rojas,⁴ Shirley M.Q. Truyenque,¹² Ana Ilda Ayala-Lugo,¹³ Ana Carolina Oliver,⁶ Lorena L. Figueiredo-Pontes,¹⁴ Fabiola Traina,¹⁴ Frederico Moreira,¹ Evandro M. Fagundes,⁸ Bruno K.L. Duarte,⁹ Analí Pamela Mora-Alferez,¹² Percy Ortiz,⁴ Jose Luis Untama,⁴ Martin S. Tallman,¹⁵ Raul C. Ribeiro,¹⁶ Arnold Ganser,¹⁷ Richard James Dillon,¹⁸ Peter J.M. Valk,¹⁹ Miguel A. Sanz,²⁰ Bob Löwenberg,¹⁹ Nancy Berliner²¹ and Eduardo M. Rego¹

¹Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Brazil; ²Dana-Farber Cancer Institute, Boston, MA, USA; ³Hospital del Salvador, Providencia, Chile; ⁴Edgardo Rebagliati Hospital, Jesus Maria, Peru; ⁵Instituto de Prevision Social, Asuncion, Paraguay; ⁶Hospital Britanico, Montevideo, Uruguay; ⁷University of Pernambuco, Recife, Brazil; ⁸Federal University of Minas Gerais, Belo Horizonte, Brazil; ⁹Universidade Estadual de Campinas, Campinas, Brazil; ¹⁰Federal University of Parana, Curitiba,

Brazil; ¹¹Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil; ¹²Instituto Nacional de Enfermedades Neoplasicas, Surquillo, Peru; ¹³Universidad Nacional de Asuncion, Asuncion, Paraguay; ¹⁴Ribeirao Preto Medical School, Ribeirao Preto, Brazil; ¹⁵Memorial Sloan Kettering Cancer Center, New York, NY, USA; ¹⁶St. Jude Children's Research Hospital, Memphis, TN, USA; ¹⁷Hannover Medical School, Hannover, Germany; ¹⁸King's College, London, UK; ¹⁹Erasmus University Medical Center, Rotterdam, the Netherlands; ²⁰Valencia University Medical School, Valencia, Spain and ²¹Brigham and Women's Hospital, Boston, MA, USA

Correspondence:

E.M. REGO - eduardo.rego@hc.fm.usp.br

<https://doi.org/10.3324/haematol.2024.286338>

Received: August 13, 2024.

Accepted: October 15, 2024.

Early view: October 31, 2024.

©2025 Ferrata Storti Foundation

Published under a CC BY-NC license 

Early death and intracranial hemorrhage prediction in acute promyelocytic leukemia: validation of a risk score within chemotherapy plus ATRA cohort from international consortium

Supplementary appendix

		Consolidation Therapy			Maintenance Therapy (2 years)
Induction Therapy		Course 1	Course 2	Course 3	
	Low risk	DNR 25 mg/m ² /day x 4 ATRA 45 mg/m ² /day x 15	MTZ 10 mg/m ² /day x 3 ATRA 45 mg/m ² /day x 15	DNR 60 mg/m ² /day x 1 ATRA 45 mg/m ² /day x 15	
	Int risk	DNR 35 mg/m ² /day x 4 ATRA 45 mg/m ² /day x 15	MTZ 10 mg/m ² /day x 3 ATRA 45 mg/m ² /day x 15	DNR 60 mg/m ² /day x 2 ATRA 45 mg/m ² /day x 15	
	High risk	DNR 25 mg/m ² /day x 4 Ara-C 1000 mg/m ² /day x 4 ATRA 45 mg/m ² /day x 15	MTZ 10 mg/m ² /day x 5 ATRA 45 mg/m ² /day x 15	DNR 60 mg/m ² /day x 1 Ara-C 150 mg/m ² /8 h x 4 ATRA 45 mg/m ² /day x 15	

Figure S1. IC-APL treatment regimen. Ara-C, cytarabine; ATRA, all trans retinoic acid; DNR, daunorubicin; IC-APL, International Consortium on